Evidence map›Paper›PMID 35845499›Full record

ArticleAnnals of translational medicine2022

Study on the clinical features and prognosis of second and third generations of COVID-19.

Chao Deng, Liping Chen, Chao Ji, Yaoming Yuan, Yu Hou, Jinghui Li

Abstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chao Deng *Department of Critical Medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Liping Chen *Department of Emergency, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Chao JiDepartment of Critical Medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Yaoming YuanDepartment of Infection, Shishou People's Hospital, Shishou, China.
Yu HouDepartment of Critical Medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Jinghui LiDepartment of Critical Medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There have been no studies examining differences in clinical manifestations and prognosis between second and third generation coronavirus disease 2019 (COVID-19) patients. Our object was to analyze the epidemiological data and correlation between clinical types and COVID-19 generations. Methods: Older than 18 years COVID-19 patients who met two of the three items listed in COVID-19 Diagnosis Protocol were enrolled and divided into two groups based on epidemiological history. Clinical characteristics (age, gender, body mass index, course), disease severity, laboratory results (platelets, white blood cells, lymphocytes, inflammatory biomarkers, alanine aminotransferase, lactate dehydrogenase, creatine kinase, myoglobin, troponin, D-dimer blood biochemical indexes), clinical types were analyzed. Two groups were compared by chi-square test, group means were compared by t test, correlation between COVID-19 generations and clinical severity and clinical types were examined by Spearman correlation analysis. Results: There were no significant differences in gender composition (P=0.488), A-DROP scores (P=0.079) nor BMI (P=0.532) between the two generations. The number of second generation patients over 60 years was significantly greater than that in third generation (P<0.001). Creatine kinase levels of third generation patients were significantly higher than those of second generation patients at admission (P=0.009) and during hospitalization (P=0.023). The troponin levels of third generation patients were significantly higher than those of second generation patients at admission (P=0.020). At discharged, the creatine kinase and troponin levels were not significantly different between the two generations. Rate of severe (P=0.130) and critical cases (P=0.314) in second generation COVID-19 patients was not significantly different from that of third generation patients. Age (ρ=0.224, P<0.001), duration (ρ=0.317, P<0.001), transmission generation (ρ=0.269, P<0.001), serum creatine kinase (ρ=0.240, P<0.001), troponin (ρ=0.296, P<0.001), C-reaction protein (ρ=0.278, P<0.001), procalcitonin levels (ρ=0.221, P=0.001), lymphocyte count (ρ=-0.245, P<0.001), and platelet count (ρ=-0.265, P<0.001) of COVID-19 patients were significantly s correlated with clinical types. Conclusions: Increased virulence may occur in specific tissues and organs during intergenerational transmission of COVID-19 virus. COVID-19 virus virulence in different regions is different. The clinical prognosis of COVID-19 patients is closely related to age, course, transmission generations, and some laboratory indicators. Transmission generation, regional differences, and laboratory indicators may have certain potential value in predicting prognosis and treatment.

Indexed as

clinical characteristicsCoronavirus disease 2019 (COVID-19)prognosistransmission generation

Identifiers

PMID35845499
PMCPMC9279802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.